IL6ST and diffuse large B-cell lymphoma: The combined results from our patient cohort and xenotransplantation models indicate that active IL‐6R/STAT3 signaling is a negative prognostic factor and therapeutic target in DLBCL; biomarkers that may be useful in predicting therapy success include the expression of IL‐6R, gp130, and phospho‐STAT3.